Viral Hepatitis C

Research and Markets - Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease.

Hepatitis C virus affects between 130–150 million individuals every year globally of which approximately 700,000 people die. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.

It was estimated that there could be rise from $18700 million to $22721.1 million in hepatitis drug market by the end of forecasting period reflecting a sluggish CAGR of 3.3%.

    Related Conference of Viral Hepatitis C

    April 08-09, 2026

    14th World Gastro Summit

    London, UK
    May 21-22, 2026

    17th International Conference on Liver Diseases & Hepatology

    Aix-en-Provence, France
    June 18-19, 2026

    9th International Congress on Viral Hepatitis

    Paris, France
    August 03-04, 2026

    21st Euro-Global Gastroenterology Conference

    London, UK
    September 29-30, 2026

    7th Global Summit on Earth Science and Climate Change

    Aix-en-Provence, France

    Viral Hepatitis C Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in